Lawyers in Talcum Powder Bellwether Lawsuit To Meet for Final Pretrial Conference Nov. 5

Lawyers in Talcum Powder Bellwether Lawsuit To Meet for Final Pretrial Conference Nov. 5

As the start of the first federal talcum powder bellwether trial approaches, plaintiffs and defendants have finalized the lawyers that will participate on their trial teams, and are preparing for a key pretrial conference early next month.

More than 90,000 women with pending Baby Powder lawsuits and Shower-to-Shower lawsuits are closely watching the bellwether case, since each of the claims raise similar allegations that Johnson & Johnson knew their talc-based products could be contaminated with asbestos, yet refused to warn women not to use the powder on their genitals.

The talcum powder litigation began more than a decade ago, and has been consolidated in the federal court system before U.S. District Judge Michael Shipp, who is overseeing coordinated discovery and pretrial proceedings out of the District of New Jersey.

However, Johnson & Johnson has spent years delaying progress in the federal courts, largely through a series of failed bankruptcy maneuvers aimed at shielding the company from liability. These efforts have stalled the start of any federal trials, even as the size of the litigation continued to grow.

While most of the litigation is centralized in the federal court system, claims are also now moving forward in various state courts including California, New Jersey and Pennsylvania.

|
|

In the federal MDL, Judge Shipp has ordered the parties to prepare for the first bellwether trial, which they agreed should be a talcum powder ovarian cancer lawsuit filed by Carter Judkins. In an August court order (PDF) he scheduled a final pretrial conference for November 5.

On October 1, plaintiffs (PDF) and defendants (PDF) submitted letters indicating which attorneys would represent Judkins and the defendants at trial. However, one of the plaintiffs’ attorneys will not be present for the November 5 conference, as he will be serving as lead trial counsel in a talcum powder trial in California state court, which is set to begin the same week.

Hundreds of similar talcum powder ovarian cancer lawsuits are filed in California state court, which plans to hold the first of three trials starting on November 3. The trial is expected to last about four weeks and will be immediately followed by two similar trials. All three of the California cases will involve two separate plaintiffs.

There are also other trials scheduled for next year in New Jersey and Pennsylvania state courts.

Although the outcomes of these bellwether trials will not be binding on other plaintiffs, they will be closely watched by lawyers involved in the litigation. If the parties still fail to reach a resolution after the bellwether trials, dozens of individual cases may begin moving forward simultaneously in different courts in the coming years.

Sign up for more legal news that could affect you or your family.


Written By: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A new lawsuit against Roblox alleges that the platform’s inadequate safety measures enabled multiple sexual predators to exploit a five-year-old girl.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.